Karo Pharma Stock

Karo Pharma EBIT Margin

Delisted·Nov 24, 2022

The EBIT Margin (Operating Margin) of Karo Pharma (KARO.ST) as of Aug 8, 2026 is 6.95 %. In the previous year, EBIT Margin (Operating Margin) was 8.67 % — a change of -19.85% (lower).

EBIT Margin

6.95 %

YoY

-19.85%

Last updated:

EBIT Margin (Operating Margin) of Karo Pharma is 2026 6.95 % . EBIT Margin (Operating Margin) of Karo Pharma was 2025 8.67 % . It decreases by -19.85% lower compared to the previous year.

For Karo Pharma, the operating (EBIT) margin of 7.0% is down versus 12.2% a few years ago.

Access this data via the Eulerpool API

Karo Pharma Stock analysis

What does Karo Pharma do? Karo Pharma AB is a Swedish pharmaceutical company specializing in the manufacturing and distribution of over-the-counter drugs and health products. The company's history dates back to 1986 when it was founded as Karo Bioforskning. Over time, the company went through several restructurings and realignments until it finally became an independent company listed on the Stockholm Stock Exchange in 2017 under the name Karo Pharma AB. Karo Pharma's business model is based on a broad portfolio of over-the-counter drugs and health products tailored to the needs of consumers in different countries and for different indications. The product range includes pain relievers, cold remedies, medications for digestive disorders, and eye care products. In addition, the company also offers dietary supplements and other health products. Karo Pharma operates in three main segments: Consumer Healthcare, Prescription Pharmaceuticals, and Out-licensing. Consumer Healthcare focuses on over-the-counter drugs and health products for end consumers. Examples include VagiVital, a medication for the treatment of vaginal yeast infections, and MolluscumVital, a product for the removal of warts. In the Prescription Pharmaceuticals segment, Karo Pharma offers prescription drugs for specific indications, such as Eklira, used in the treatment of chronic obstructive pulmonary disease (COPD). The Out-licensing segment involves the licensing of products and technologies to other companies. Karo Pharma has a particular focus on the development of products based on natural active ingredients. For example, Prenoxdiazin, used for pain relief, is based on an extract from the root of peonies. Natural ingredients are preferred in the development of other products as well, to maximize their compatibility and effectiveness. Overall, Karo Pharma's portfolio includes more than 20 brands and over 100 products distributed in various countries. The company is headquartered in Stockholm and operates in several European countries, as well as in the United States and Canada. Karo Pharma emphasizes close collaboration with doctors and pharmacists to ensure that its products meet the needs of consumers optimally. In recent years, Karo Pharma has become the leading provider of over-the-counter drugs and health products in Scandinavia and now plans to expand its presence in other European countries. The company aims to strengthen its position as the leading provider of over-the-counter drugs and health products, with a focus on innovative and natural solutions, through a combination of organic growth and targeted acquisitions of companies with complementary products and technologies. Karo Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Karo Pharma stock

EBIT Margin (Operating Margin) of Karo Pharma is 6.95 % in 2026.

EBIT Margin (Operating Margin) of Karo Pharma changed from 8.67 % to 6.95 %, representing a -19.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Karo Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Karo Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — Karo Pharma

All Key Metrics — Karo Pharma